Crestor (Rosuvastatin)

Generic Name

Rosuvastatin

Brand Names

Crestor, Rosuvastain

FDA approval date: July 19, 2016

Classification: HMG-CoA Reductase Inhibitor

Form: Tablet

What is Crestor (Rosuvastatin)?

CRESTOR is indicated: To reduce the risk of major adverse cardiovascular events in adults at increased risk for CV events., As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol : ∘ in adults with hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia . ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia. CRESTOR is an HMG Co‑A reductase inhibitor indicated: , To reduce the risk of major adverse cardiovascular events in adults at increased risk for CV events., As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol : ∘ in adults with primary hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia . ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20...

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a...

View All Clinical Trials